In recent years, immunotherapy, cell therapy, and gene therapy have taken center stage as new approaches for eliminating malignant tumors.
A technology that overcomes this lack of accuracy is a polymer nanoshell delivery mechanism,
developed and patented by a national research institute in Taiwan. The combinatorial PLGA-based polymer nanoshell encapsulates the peptide antigen of interest, reducing reactogenic adverse effects and triggering precise multivalent immune potentiation, resulting in a yield of nearly 30% accuracy rate (>29%) in CD8+ T cell stimulation. ABC hopes that the high potency and safety profile of the vaccine renders it capable of minimizing future vaccination regimen and duration in improving treatment outcome.
The first neoantigen cancer vaccines to be on ABC Treatment Access Platform targets Colorectal Carcinoma. ABC believes that both a personalized cancer vaccine and a neoantigen-based therapeutic plan are around the corner in the future of oncology medicine.
*Note: For complete description of therapeutics and diagnostics with citations, please refer to ABC ICO Prospectus